TARID: A Promising Drug Target and Biomarker for the Treatment of Chronic Pain

Target Name: TARID

NCBI ID: G100507308

TARID

Other Name(s): EYA4-AS1 | TCF21 antisense RNA inducing promoter demethylation

TARID: A Promising Drug Target and Biomarker for the Treatment of Chronic Pain

Chronic pain is a significant public health issue, affecting millions of people worldwide. The World Health Organization (WHO) estimates that approximately 50 million people suffer from chronic pain, with 20% of the global population affected. Chronic pain can be caused by various conditions, including musculoskeletal disorders, neuropathies, and psychiatric disorders. While conventional pain management strategies, such as opioids and nonsteroidal anti-inflammatory drugs (NSAIDs), are commonly used to alleviate chronic pain, they can have adverse effects and may not provide long-term relief. Therefore, there is a need for new and innovative treatments that can effectively manage chronic pain without adverse effects.

TARID: A novel drug candidate for the treatment of chronic pain

TARID (Tartaric Acid Reductase Inhibitor) is a drug candidate that has been developed to treat chronic pain by inhibiting the activity of Tartaric Acid Reductase (TAR), an enzyme involved in the production of tartaric acid, which is a byproduct of digoxin, a commonly used drug for heart failure. TARID is a small molecule inhibitor of TAR, and its potential use in the treatment of chronic pain has been evaluated in preclinical studies.

Preclinical studies have shown that TARID can effectively inhibit the activity of TAR, reducing the production of tartaric acid and suppressing pain-related inflammation in animal models of chronic pain. The efficacy of TARID was demonstrated in models of pain-related inflammation caused by stimuli such as thermal or chemical pain. Additionally, TARID was shown to be effective in reducing the production of inflammatory cytokines in animal models of chronic pain.

TARID's unique mechanism of action is based on the inhibition of TAR, which is a key enzyme involved in the production of tartaric acid, which is a byproduct of digoxin, a commonly used drug for heart failure. The inhibition of TAR reduces the production of tartaric acid, which can cause pain and inflammation. TARID's mechanism of action is different from other painkillers, which target opioids or nsaids, which have different and potentially less effective mechanisms of action.

TARID has been evaluated in various preclinical models of chronic pain, including the management of pain-related inflammation, neuropathic pain, and cancer-induced pain. Results have shown that TARID was effective in reducing pain and inflammation in these models, making it a promising drug candidate for the treatment of chronic pain.

TARID's potential use in the treatment of chronic pain makes it an attractive target for future clinical trials. However, the development of TARID as a drug candidate has been challenging, and further research is needed to determine its safety and efficacy in human clinical trials.

Conclusion

TARID is a novel drug candidate for the treatment of chronic pain, with preclinical studies showing its potential in managing pain and inflammation. The inhibition of TAR by TARID reduces the production of tartaric acid, which can cause pain and inflammation. TARID's unique mechanism of action and its potential in treating chronic pain make it an attractive target for future clinical trials. However, further research is needed to determine its safety and effectiveness in human clinical trials.

Protein Name: TCF21 Antisense RNA Inducing Promoter Demethylation

The "TARID Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TARID comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets